Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Echo Therapeutics is angling to get regulatory approval for its wireless, non-invasive glucose monitor, and the company now has a $20 million line of credit to speed the process, thanks to Platinum-Montaur Life Sciences.
Echo Therapeutics is reporting positive clinical trial results for its transdermal glucose monitor, and its CEO will get a chance to discuss them on national TV.
Philadelphia-based Echo Therapeutics took a $16.7 million loss in 2011, a year in which the company had planned to launch its needle-free, transdermal drug delivery platform, the Prelude SkinPrep System.
When last we left Echo Therapeutics in February , the Franklin, MA-based company was speeding up the launch of its Prelude SkinPrep System for transdermal drug delivery after receiving word from the
Franklin, MA-based Echo Therapeutics is speeding up the launch of its non-invasive drug delivery system and announced plans to list on a national exchange. The company, along with its partners